hmg-coa reductase inhibitor atorvastatin promotes th2 bias reverses paralysis central nervous system autoimmune disease 
statins hydroxy--methylglutaryl coenzyme hmg-coa reductase inhibitors approved cholesterol reduction may also beneficial treatment inflammatory diseases- atorvastatin lipitor tested chronic relapsing experimental autoimmune encephalomyelitis cd4+ th1-mediated central nervous system cns demyelinating disease model multiple sclerosis show oral atorvastatin prevented reversed chronic relapsing paralysis atorvastatin induced stat6 phosphorylation secretion th2 cytokines interleukin il- il il- transforming growth factor tgf-beta conversely stat4 phosphorylation inhibited secretion th1 cytokines il- il- interferon ifn-gamma tumour necrosis factor tnf-alpha suppressed atorvastatin promoted differentiation th0 cells th2 cells adoptive transfer th2 cells protected recipient mice eae induction atorvastatin reduced cns infiltration major histocompatibility complex mhc class ii expression treatment microglia inhibited ifn-gamma-inducible transcription multiple mhc class ii transactivator ciita promoters suppressed class ii upregulation atorvastatin suppressed ifn-gamma-inducible expression cd40 cd80 cd86 co-stimulatory molecules l-mevalonate product hmg-coa reductase reversed atorvastatins effects antigen-presenting cells apc t cells atorvastatin treatment either apc t cells suppressed antigen-specific t-cell activation thus atorvastatin pleiotropic immunomodulatory effects involving apc t-cell compartments statins may beneficial multiple sclerosis th1-mediated autoimmune diseases 
